Brown Advisory’s Relay Therapeutics RLAY Stock Holding History

Brown Advisory’s Portfolio RLAY Stock Details RLAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-12,914	Closed	-$397K	–	1224
2021 Q4	$397K	Buy	+12,914	New	+$408K	﹤0.01%	946

Other funds holding RLAY

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Brown Advisory's RLAY Position: Q1 2022 in Review

Brown Advisory sold out of Relay Therapeutics (RLAY) in Q1 2022, closing a stake of 12,914 shares — an estimated $397K sold.

Brown Advisory first reported a position in RLAY in Q4 2021 and held it in 1 quarter. The position peaked at $397K in Q4 2021. 140 funds tracked by Wall St. Rank hold RLAY as of Q1 2022.

Brown Advisory reported no remaining Relay Therapeutics position as of Q1 2022 after selling out during the quarter.
Brown Advisory sold 12,914 Relay Therapeutics shares in Q1 2022, an estimated $397K.
Brown Advisory first reported a position in Relay Therapeutics in Q4 2021 and held it in 1 quarter.
Brown Advisory's Relay Therapeutics position peaked at $397K in Q4 2021.
140 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2022.

Based on Brown Advisory's 13F filing for Q1 2022, filed 9 May 2022.